Disclaimer: This article is for informational and educational purposes only. BPC-157 is a research compound and is not approved by the FDA, Health Canada, or any other regulatory agency for human use. All content on this site pertains to research purposes only. Nothing here constitutes medical advice.
If you’ve been following peptide research news in 2026, you’ve likely seen headlines about BPC-157 being removed from the FDA’s “Category 2” list. Researchers and sourcing communities are actively debating what this means — and there’s significant confusion between “removal from Category 2,” regulatory approval, and legal compounding status.
This post cuts through the noise and explains exactly where BPC-157 stands under U.S. and Canadian regulatory frameworks as of May 2026.
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It has been studied in preclinical models for its potential effects on tissue repair, musculoskeletal recovery, gastrointestinal integrity, and angiogenesis.
The compound has attracted substantial interest in research communities due to published animal studies suggesting roles in wound healing, tendon and ligament repair, and gastroprotection. It is not approved for human therapeutic use by the FDA, Health Canada, or the European Medicines Agency.
The FDA 503A “Category” System, Explained
To understand the April 2026 update, you need to understand how the FDA categorizes bulk drug substances for compounding.
Under Section 503A of the Food, Drug, and Cosmetic Act, compounding pharmacies can prepare customized drug formulations — but only using certain ingredients. The FDA evaluates bulk drug substances through a nomination and review process, categorizing them as:
- Category 1: Nominated; under review for possible inclusion on the 503A bulks list (i.e., allowed for compounding under specific conditions)
- Category 2: Nominated but determined to be inappropriate for compounding — these substances present safety concerns, lack clinical evidence, or are otherwise unsuitable
- Not nominated / Not listed: Outside the formal review process
A substance on the Category 1 list can be used by 503A compounding pharmacies while under review. A substance on the Category 2 list is explicitly flagged as not appropriate for inclusion on the bulks list.
What the April 2026 Update Actually Did
On April 22, 2026, the FDA published an update to its 503A bulk drug substance list affecting several peptides, including BPC-157 and TB-500 (Thymosin Beta-4 fragment). Specifically, BPC-157 was removed from Category 2.
Here is what that removal does mean:
- BPC-157 is no longer on the FDA’s explicit list of substances deemed inappropriate for 503A compounding
- It moves into a regulatory gray zone — it is neither approved for compounding nor formally prohibited under the updated list
Here is what that removal does not mean:
- It is not FDA approval for any use
- It is not authorization for compounding pharmacies to use BPC-157 freely
- It is not a signal that human use is considered safe or effective by any agency
- Compounding a substance not on the 503A bulks list without a specific regulatory pathway remains legally risky for pharmacies
The practical effect: BPC-157 is now in a holding pattern. Its future status will be significantly influenced by upcoming FDA advisory committee meetings.
The PCAC Meeting: July 23–24, 2026
The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory body that reviews substances nominated for the 503A and 503B bulks lists. A PCAC meeting scheduled for July 23–24, 2026 will directly address several peptides that were part of recent list updates, including BPC-157, TB-500, MOTS-c, KPV, DSIP, Semax, and Epitalon.
The Federal Register notice for this meeting (published April 2026) confirms the committee will evaluate safety and efficacy evidence for these compounds. The PCAC’s recommendations are not legally binding, but they carry significant weight in the FDA’s final rulemaking.
What researchers and the compounding industry are watching:
- Will the PCAC recommend BPC-157 for inclusion on the Category 1 (under review, permitted) list?
- Will evidence from published animal studies be sufficient, or will the committee require human clinical trial data?
- How will the outcome affect 503B outsourcing facilities, which operate under different rules than 503A pharmacies?
The July meeting represents the next major regulatory milestone for BPC-157. An outcome favoring inclusion on the Category 1 list would open a clearer (though still tightly regulated) pathway for compounding pharmacies. An adverse recommendation would substantially increase restrictions.
BPC-157 and Canadian Research Context
For researchers in Canada, BPC-157 exists in a parallel regulatory environment. Health Canada has not approved BPC-157 for any therapeutic indication, and it does not appear on the List of Drugs for Exceptional Importation or Sale. Under the Food and Drugs Act, importing or selling unapproved drug substances for human use is not permitted.
That said, BPC-157 is widely discussed in Canadian research and academic contexts, and research-grade supplies are available internationally for in vitro and animal model work. Researchers should consult current Health Canada guidance and ensure any use complies with applicable regulations for their institution and jurisdiction.
BPC-157 vs TB-500: Are They in the Same Regulatory Boat?
TB-500 (the synthetic analogue of Thymosin Beta-4 fragment 17-23) was also removed from FDA Category 2 in the April 2026 update. The two compounds are often discussed together — colloquially as the “Wolverine stack” in research and performance communities — and both are headed into the same PCAC review process.
Mechanistically, BPC-157 and TB-500 have been studied for overlapping but distinct effects:
| Property | BPC-157 | TB-500 |
|—|—|—|
| Primary research area | GI protection, tendon/ligament repair, angiogenesis | Actin-binding, skeletal muscle repair, wound healing |
| Origin | Derived from gastric protein sequence | Derived from Thymosin Beta-4 |
| Preclinical data | Extensive rodent studies | Moderate rodent and equine studies |
| FDA status (May 2026) | Not on 503A bulks list; Category 2 removed | Not on 503A bulks list; Category 2 removed |
| WADA status | Prohibited under S0 (non-approved substances) | Prohibited under S0 |
Both remain prohibited by the World Anti-Doping Agency under the S0 category, which covers any pharmacological substance not currently approved for human therapeutic use by a recognized regulatory authority.
What Researchers Should Know Right Now
If you’re following BPC-157 research or working with this compound in preclinical contexts, here is the practical summary for May 2026:
1. Regulatory status is in flux. The April 2026 Category 2 removal creates uncertainty, not freedom. The July PCAC meeting will significantly shape the next 12–24 months of regulatory direction.
2. Compounding pharmacy availability may shift. Some 503A pharmacies may interpret the Category 2 removal as reducing explicit prohibitions, while others will wait for clearer guidance. Researchers sourcing through compounding pharmacies should verify current policy.
3. Research-grade purity and testing matter more, not less. As the regulatory environment evolves, quality assurance documentation (CoA, HPLC purity, sterility testing) becomes a more important differentiator for legitimate research use.
4. No change in human therapeutic approval. Nothing in the April 2026 update changes the fundamental position: BPC-157 is not approved for human use in the U.S., Canada, or the EU.
Frequently Asked Questions
Q: Is BPC-157 legal to buy in the U.S. in 2026?
A: The legal landscape is nuanced. BPC-157 is not an FDA-approved drug, and it is not on the 503A compounding bulks list. Selling it for human consumption is not legal under FDA rules. Research-grade BPC-157 sold strictly for laboratory and research purposes occupies a gray area that is subject to ongoing regulatory development. The July 2026 PCAC meeting will clarify the pathway forward for compounding use.
Q: What does removing BPC-157 from Category 2 actually change for researchers?
A: In practical terms, not much immediately. Category 2 removal means the compound is no longer on the FDA’s explicit “not appropriate for compounding” list, but it does not move it onto an approved or permitted list. It’s more of a reset than a green light.
Q: Will BPC-157 become legally compoundable after the PCAC meeting?
A: That depends on the committee’s recommendation. If the PCAC recommends BPC-157 for inclusion on the 503A bulks list, it could eventually be compounded by licensed 503A pharmacies under specific conditions. This process typically takes additional months even after a positive recommendation.
Q: Is BPC-157 banned in competitive sports?
A: Yes. WADA prohibits BPC-157 under the S0 category (non-approved substances), which applies to any substance not currently approved for human use by a regulatory agency. This prohibition applies in and out of competition.
Q: Where can I track updates to the FDA 503A peptide list?
A: The FDA maintains the current 503A bulks list on its website. The Federal Register publishes PCAC meeting notices in advance. The next major update opportunity is the July 23–24, 2026 PCAC meeting.
Conclusion
The April 2026 removal of BPC-157 from FDA Category 2 is a meaningful — but frequently misread — regulatory event. It does not approve BPC-157, authorize its compounding, or signal that human use is considered safe. What it does do is open a review pathway toward potential future inclusion on the 503A bulks list, pending the July 2026 PCAC meeting.
For researchers working with BPC-157 in preclinical contexts, the most important takeaway is: stay informed as the PCAC process unfolds, maintain rigorous quality standards for any research-grade material, and ensure your work is compliant with all applicable regulations.
WebberScience carries research-grade peptides with full third-party testing documentation. Browse our current catalogue for compounds available for legitimate laboratory research use.
Sources: FDA 503A Bulk Drug Substances list (FDA.gov), Federal Register PCAC meeting notice (April 2026), World Anti-Doping Agency Prohibited List 2026. This article does not constitute legal or medical advice.